<?xml version="1.0" encoding="UTF-8"?>
<p>Currently, the most effective treatment for most patients with CCS remains surgical resection, with only a small fraction of patients benefiting from conventional cytotoxic chemotherapy (
 <xref rid="B6" ref-type="bibr">6</xref>). Some of the latest potential therapeutic targets of CCS, such as MET, PDGFRA/B, and HDAC, have been identified. Due to the identification of these targets, some small molecules and monoclonal antibodies, such as sunitinib, sorafenib, and crizotinib, are in clinical trials. These treatments offer new hope for improving the prognosis of patients with this rare invasive disease (
 <xref rid="B2" ref-type="bibr">2</xref>, 
 <xref rid="B13" ref-type="bibr">13</xref>).
</p>
